A204 Transfection Reagent

Catalog # 1703 - 0.5 mL        $ 87.00 Catalog # 1704 - 1.5 mL        $ 179.00 Transfection reagent for A204 cells Protocols provided for transfection of siRNA and microRNA Kit includes Transfection Enhancer reagent and recommended transfection protocols High transfection efficiency Optimized for human rhabdomyosarcoma cells Work in presence of serum Compatible with transfection in any plate format Reliable results Cost-effective transfection Developed and manufactured by Altogen Biosystems Transfection Efficiency: Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR, Western blot. Transfection Protocol: Transfection protocols are provided with the purchase of the reagent.

DATA

Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).

Transfection Resource

Visit Altogen Biosystems Transfection Resource: RNAi applications (siRNA transfection, microRNA transfection, plasmid DNA transfection), stable and transient DNA transfection, delivery methods, electroporation, microinjection, dendrimer-based, non-viral and virus-mediated gene delivery, liposome and non-liposomal reagents. Transfection of cancer cell lines vs primary cultures. RNA Interference as a research tool for gene expression studies, gene silencing in neuronal cells, RNAi therapeutics and In Vivo Transfection Reagents from Altogen Biosystems.

Human Rhabdomyosarcoma Cells

A204 was derived from the muscle tissue of a one year old male with rhabdomyosarcoma. These are epithelial cells which were reported to form small malignant tumors in nude mice consistent with embryonic rhabdomyosarcoma. A204 cells have shown limited sensitivity to Natural Killer cell cytotoxicity. In an examination of the transcriptional and post-transcriptional regulation of the human laminin beta2 chain in human tumor cell lines, A204 expressed the laminin beta-2 chain mRNA and secreted laminin heterotrimers containing the beta2 chain. A204 has been studied in culture for its capacity to synthesize collagen types and other extracellular matrix proteins. The cells synthesized and secreted into the culture medium collagenous proteins. A204 was found to lay down a highly insoluble matrix composed mainly of a1 type-XI and a2 type-V collagen chains. Since the A204 cell line does not produce other collagen types, it may prove useful in further studies of the biosynthesis of type V procollagen.

Transfection Resource

siRNA Transfection || Transfection Methods || Stable Transfection || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Transfection || In Vivo Transfection Reagents || Cell Line Specific Transfection Reagents

Featured Products

In Vivo Transfection Reagents || Fibroblast Cells Transfection Reagent || Astrocyte Cells Transfection Reagent || HEK-293 Transfection Reagent || MEF Transfection Reagent || HepG2 Transfection Reagent || CHO Reagent || MDA-MB Transfection Reagent || Cos7 Transfection Reagent || A549 Transfection Reagent || NIH3T3 Reagent || HUVEC Transfection Reagent || LNCaP Transfection Reagent || MCF-7 Reagent || PC-12 Reagent

Altogen Research Services

Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including - generation of stable cell lines, RNA Interference (RNAi) services, assay development, screening and transfection services. Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Altogen Services offers generation of stable cell lines by transforming the cell line of choice to stably express gene of interest or shRNA-encoding construct. Cloning and shRNA expression services are available.